Research Peptides
RESEARCH USE ONLY
Research Peptides
RESEARCH USE ONLY
| Ingredients | Tirzepatide (LY3298176) — 39 aa dual GIP/GLP-1 receptor agonist, C20 diacid side chain |
|---|---|
| Storage | Store refrigerated at 2–8°C, protect from light, do not freeze. |
| Shelf life | 24 months |
| SKU | Content - Spec | Pack | Price | Stock |
|---|---|---|---|---|
| TR5 | 5mg | 10 vials | $49.00 | In stock |
| TR10 | 10mg | 10 vials | $69.00 | In stock |
| TR15 | 15mg | 10 vials | $89.00 | In stock |
| TR20 | 20mg | 10 vials | $99.00 | In stock |
| TR30 | 30mg | 10 vials | $139.00 | In stock |
| TR40 | 40mg | 10 vials | $169.00 | In stock |
| TR50 | 50mg | 10 vials | $189.00 | In stock |
| TR60 | 60mg | 10 vials | $209.00 | In stock |
Research reagents are for laboratory and in-vitro research only. Not for human use.
Research reagents are not supplied as medicines and must not be used for diagnosis, treatment, prevention, clinical procedures or self-medication. Product information must not be used as administration or dosing guidance.
For accessories and consumables, follow their own specifications and documented intended use.
Tirzepatide is a dual GIP/GLP-1 receptor agonist used for weight management and glycemic control in type 2 diabetes. It promotes fat loss by suppressing appetite and delaying gastric emptying.
Suppresses appetite, reduces caloric intake; delays gastric emptying, increases satiety; improves insulin sensitivity, lowers blood glucose; promotes lipolysis and energy expenditure; achieves significant weight loss, especially in obese or overweight individuals.
Subcutaneous injection once weekly. Initial dose 2.5 mg, increased to 5 mg after 4 weeks. Based on tolerability, may be further increased to 10 mg or 15 mg for maintenance. Specific dosage and cycle should be followed as per physician's advice. Do not combine with other GLP-1 receptor agonists.
Obese or overweight individuals with metabolic syndrome (e.g., hypertension, hyperlipidemia); patients with type 2 diabetes requiring enhanced glycemic control; individuals with inadequate weight loss outcomes from diet and exercise interventions.